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Abstract
Oncotype DX testing (ODX), a tumor gene expression test, may improve breast cancer care, 
however communicating results remains challenging. We identified patient-centered 
communication strategies/gaps for discussing ODX results. We applied a patient-centered 
communication framework to analyze qualitative interviews with oncologists about how they 
communicate about ODX with patients, using template analysis in Atlas.ti. Overall, providers 
discussed four patient-centered communication domains: exchanging information, assessing 
uncertainty, making decisions and cross-cutting themes. Providers did not report discussing 
emotional aspects of managing uncertainty, assessing decision-making preferences, and evaluating 
decisions. A patient-centered approach may be a model for communicating about tumor gene 
expression tests.
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1. Introduction
In 2015, the Precision Medicine Initiative was announced with the ultimate goal of moving 
genetic and genomic technologies into clinical care. Cancer care has already become more 
targeted, as providers use unique tumor genetics to inform treatment plans. Oncotype DX 
(Genomic Health, Redwood City, CA) (ODX) is an example of a precision medicine tool 
that is currently recommended in clinical guidelines for women with node negative, 
hormone receptor positive breast cancer [1]. ODX is a 21-tumor gene expression test that 
predicts average rate of 10-year distant recurrence and benefit from adjuvant chemotherapy 
by categorizing women into low (recommended to forgo chemotherapy), intermediate 
(unclear evidence for chemotherapy benefit), and high (recommended to have 
chemotherapy) risk groups [2, 3]. Evidence suggests that ODX decreases overuse of adjuvant 
chemotherapy among women with low risk tumors, protecting women from the unnecessary 
costs and harms [4, 5].
While ODX testing has the potential to improve the quality of cancer care, providers have 
reported barriers to communicating with patients about ODX testing [6], and patients 
demonstrate low recall accuracy about ODX testing [7]. This suggests potential gaps and 
challenges in patient-provider communication about genetic technologies. As use of such 
technologies increases, high-quality, patient-centered communication will be critical to 
adequately describe these tests and results to patients.
The NCI Framework for Patient Centered Communication suggests that effective patient-
centered communication in cancer care requires: exchanging information, fostering healing 
relationships, recognizing and responding to emotions, managing uncertainty, making 
decisions, and enabling patient self-management; the framework also contains a cross-
cutting domain including time, setting, roles of communication, and partnership-building [8]. 
Our goal was to use this framework to examine current practices for discussing ODX testing 
with patients, and to identify aspects of patient-centered communication that are and are not 
being employed by providers.
2. Materials and Methods
2.1 Study Design
In 2014, we conducted ~30-minute semi-structured telephone interviews with oncologists 
across North Carolina (NC) until saturation of themes was reached. A qualitative approach 
allowed for a nuanced understanding of the complex communication and decision-making 
that occurs about ODX in the clinical encounter and cannot be adequately captured through 
quantitative analyses alone. Our interview guide sought to elicit providers’ perspectives 
about barriers and facilitators of using ODX testing in clinical practice; this included use of 
ODX testing for patients with early stage, hormone receptor positive breast cancer, with 
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lymph node negative or lymph node positive disease. Of note, at the time of the study, ODX 
was only guideline recommended for women with node negative breast cancer. We also 
collected information about how providers communicate information about ODX testing and 
results to their patients. Interviews were conducted by one author (MCR); a second author 
(AB) listened, identified areas for probing, and took notes. All interviews were digitally 
recorded, professionally transcribed, de-identified and transferred to Atlas.ti (Berlin, 
Germany) for analysis.
2.2 Participants
We used purposive sampling to identify surgical and medical oncologists who practice in 
community or academic settings using the NC Oncology Association website, NC Medical 
Board website, and referrals from oncologists at the University of North Carolina-Chapel 
Hill. Providers were emailed or faxed a recruitment letter asking them to contact us, should 
they wish to participate. Providers were eligible if they practiced in NC and saw at least five 
breast cancer patients/week to establish care, to undergo treatment, or for follow-up. After 
scheduling a phone interview, providers completed an electronic informed consent and brief 
demographic survey. Providers received $100 gift cards for participating. Informed consent 
was obtained from all individual participants included in the study.
2.3 Data Analysis
We used a method called “template analysis”, which combines inductive and deductive 
approaches to coding interview transcripts with emergent and a priori codes or themes. 
Template analysis allows a priori codes to be modified, removed and augmented [9]. We 
applied an a priori set of codes (a template) to the first five transcripts using Atlas.ti. A 
conceptual framework from implementation science was used to compile the semi-structured 
interview guide and a priori codes, focusing on the adoption and use of ODX testing for 
treatment decision-making [10]. Next, the template was revised and emergent thematic codes 
were added to create the final coding template, which was expanded to include provider 
communication codes prior to and after ordering ODX testing (Electronic Supplement: 
Appendix 1). This final code template was applied to all transcripts by two coders (MCR, 
AB). Consensus was reached on coding for the first five transcripts to ensure high inter-rater 
reliability; coded transcripts were merged across coders using Atlas.ti. This paper focuses on 
results about ODX communication.
2.4 Conceptual Model
During data analysis, we focused on four domains of the patient-centered communication 
framework [8] that were most relevant to decision-making about ordering and using ODX 
testing for treatment decision-making (Electronic Supplement: Appendix 2). Of note, this 
framework differs from the conceptual model used to develop the interview guide. First, 
exchanging information is the reciprocal exchange of information between the patient and 
provider about ODX testing and chemotherapy by (a) sharing information, (b) exploring 
knowledge, beliefs and information needs, (c) providing information resources, and (d) 
facilitating the understanding of information. Second, managing uncertainty includes four 
subdomains: identifying uncertainty (e.g., whether to take chemotherapy, how to interpret 
intermediate ODX risk scores); understanding uncertainty; emotion-focused management 
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strategies (e.g., reducing anxiety and stress caused by uncertainty around treatment decision-
making); and problem-focused management strategies (e.g., taking steps to reduce 
uncertainty, such as creating a plan for interpreting intermediate risk scores). Third, the 
making decisions domain focuses on the decision-making process (e.g., whether to use ODX 
testing, how to use results in chemotherapy decision-making). Subdomains include 
communicating about decisional needs (e.g., whether ODX testing is necessary for 
chemotherapy decision-making), preparing for decision (e.g., considering the choices for 
ODX testing and chemotherapy decision-making), making a choice and implementing a plan 
(e.g., whether to use ODX testing, subsequent treatment plans), and assessing decision-
quality. Finally, there are cross cutting themes include the timing, setting, and care team 
roles for communication during the ODX test decision-making process.
3. Results
We reached thematic saturation after 15 interviews (5 surgical and 10 medical oncologists). 
The majority worked in academically-affiliated settings; on average, providers had practiced 
for 16 years, saw 25 patients/week (56% of whom had breast cancer), and ordered about 4 
ODX tests/month (Table 1).
3.1 Exchanging Information
3.1.1 Sharing information—During initial conversations (before ordering ODX), all but 
one provider discussed sharing general information with patients about cancer biology, gene 
expression, risk of recurrence, ODX, and adjuvant chemotherapy. They described discussing 
how the test was developed (n=3), its costs (n=4), and how ODX fits into their cancer care 
plan (n=8). As one provider mentioned, “the more information [patients] can have, the more 
comfortable they are.”
3.1.2 Exploring knowledge, beliefs, and information needs and preferences—
One third of providers discussed exploring knowledge and beliefs, patient preferences, and 
patient needs, reciprocally with patients. They discussed the importance of assessing patient 
preferences for chemotherapy prior to ordering ODX testing. For example, if a patient had 
an informed preference against chemotherapy, providers discussed not ordering ODX 
testing, as the result would not inform decision-making. However, some providers 
questioned whether patients’ preferences about chemotherapy were informed, because of 
patients’ “preconceived notions against chemotherapy”:
I think a lot of times they may be generalizing all cancer. And as we know, there are 
certain cancers that are much more aggressive than breast cancer and many times it 
will all be sort of lumped together in the patient’s head. So, sometimes it includes 
reeducation about what breast cancer is, how it behaves and how the chemotherapy 
might differ for a breast cancer patient as opposed to a lymphoma patient who gets 
five chemotherapeutic agents in one cycle.
When eliciting patient preferences, providers mentioned that reciprocal exchange of 
information facilitated shared decision-making, which activated women:
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I think it’s also empowered a lot of women to be able to tell their doctors why or 
why not they think chemo would be a benefit to them. So, it’s opened up the 
discussion between providers and patients.
About 1/3 of doctors mentioned being sensitive to potential financial concerns about ODX 
testing:
Before the test is run, the patient is aware and agrees to that and we make certain 
that the finances are not going to be burdensome.
3.1.3 Providing informational resources—Most oncologists provided patients with 
resources, including pamphlets and sample ODX reports to help frame and prepare for 
discussions about the test and results and as a reference at home:
What’s difficult I think is having the initial discussion about the Oncotype …So, 
what I’ve done is…print out sort of a mock report. And so I tend to use that in my 
discussion. So I can show them what the results look like and we can talk about the 
low, intermediate, high-risk group …. That way when they come back for their 
results, they already know “well, what group am I in?” It’s a much easier 
discussion at that point.
The most commonly discussed strategy to facilitate patients’ assimilation and recall of 
information was repeated educational sessions about ODX testing both before it was ordered 
and after results were returned. About 40% of providers reported that they used multiple 
techniques to facilitate assimilation of complex concepts such as risk of recurrence and the 
ODX recurrence score. For example, they framed recurrence scores as favorable news for 
women with low and intermediate risk scores:
, I’ll often say to people, “Look. In the next 10 years there’s a 7% chance of it 
coming back.” But what that really means is there’s a 93% chance it won’t. And so 
I’ll point that out because those numbers look-- 13%, that’s terrible. But, actually 
it’s 87% it won’t, and I’ll always make them understand that number.
Three providers discussed sharing risk of recurrence scores in absolute terms with patients, 
for example:
… We try to not really talk in [relative] numbers… More like “Out of 100 people 
being treated, three people will have benefitted and 97 will maybe go through it 
without having needed it.”
Six providers used relative risks to describe risk of recurrence. One provider described:
Chemotherapy is going to give you a 3% benefit over endocrine therapy,” 
everybody [would say]”no,” right?…But if you say like “you’re going to have a 
50% reduction but it’s from 6% to 3%, people are like “I better take the chemo!”… 
It’s a really big deal.
Two providers used metaphors as a technique both to introduce information and also to help 
patients assimilate the complex nature of risk. For example, to distinguish population and 
individual risks, one provider said:
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One of the examples that I use there is…if you’re the third-grade teacher and the 
second-grade teacher says, “here’s a B class.” Well, maybe there’s 30 kids and even 
though they average a B they don’t all make a B and some of them are smart and 
make an A and some of them are not so smart and make D’s or whatever. And so 
just trying to use that example to say every two centimeter that’s node negative and 
ER positive, while we might overall estimate that that’s a 20% risk of recurrence, 
you know, maybe there are some that the risk is less than 10% and there are some 
where it’s maybe greater than 30 and this is what the test is designed to do.
Furthermore, some providers used analogies for describing how ODX testing works, for 
example:
I usually explain it by saying a couple different ways…You might [see] somebody 
that’s really well dressed and…got a nice suit on, but they might be some bad 
criminal or you might see somebody who looks like they live in the street and 
might be a completely honest person. I’ll say, “Cancer cells can be the same way. 
They can look bad and behave well or vice versa.”
Other providers discussed ODX testing more technically, in the context of tumor biology:
…[I characterize] it as a first generation genomic test and explain that it’s really 
looking at the biology of the cancer. We’re measuring these genes that are 
expressed in the tumor itself and that is a way of trying to get a better handle on the 
aggressiveness or lack of aggressiveness of the biology of the cancer. But then I go 
on to explain that the test actually is measuring the estrogen and progesterone and 
HER2 receptors in a different way with a different technique and that it is also 
measuring the growth rate, proliferation rates that kind of lines up with the grade of 
their tumor as well.
Overall, most providers gauged patients’ baseline knowledge and perceptions, provided 
information and resources, and used multiple strategies to describe ODX testing and related, 
complex concepts (e.g., risk of recurrence) to enhance information exchange during 
chemotherapy decision-making.
3.2 Assessing Uncertainty
3.2.1 Constructing, defining, assessing and understanding uncertainty—Over 
1/3 of providers identified and discussed the uncertainty around adjuvant chemotherapy 
benefit with patients, and framed ODX testing as a way to help manage uncertainty about 
chemotherapy decision-making. This discussion often extended to risk reduction:
If they are an appropriate person to consider [for ODX] then I usually talk to them 
about [chemotherapy]…. And I’ll tell them we’ve typically used (chemotherapy) 
before this test and now we have this new test that has a little bit better risk 
stratification for this particular lump of women who fall in this category of node 
negative, ER positive tumors. And it can help us decide a little bit more clearly if 
they’re higher or lower risk and it can also help us decide if we think chemotherapy 
is going to be beneficial or not or how beneficial.
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Current evidence is unclear whether women with intermediate ODX risk scores receive 
significant benefit from adjuvant chemotherapy, as such most providers discussed 
uncertainty about chemotherapy benefit for patients with intermediate ODX risk scores:
I say, “If you come back intermediate, you come back in and you and I talk about 
what to do….” Again, that’s always a second conversation if they come back in that 
gray area.
A few providers discussed the overall uncertainty about ODX testing and risk of recurrence:
And I’ll try to tell them that this is based on how they did the study where they 
developed the test and they validated it…And I try to tell them that it’s not a crystal 
ball. It’s not written in stone. This is the way it works but this gives us a pretty good 
estimate.
3.2.2 Problem-based management strategies—Providers formed actionable 
problem-based plans to manage uncertainty around the adjuvant chemotherapy decision. 
Providers explained how test results reduce uncertainty about chemotherapy benefit for 
women who have tumors with low and high risk scores.
I basically just say, “Look. [Results are] split into three categories: low, medium 
and high. If you come back high risk, this is a more aggressive tumor, more likely 
to spread and you would benefit from chemotherapy.” Then I say the exact opposite 
for low risk.
Providers emphasized to patients that the ODX results would not eliminate all uncertainty 
around adjuvant chemotherapy decision-making. Instead, they developed management plans 
to prepare patients for uncertainty if their tumors were intermediate risk. One provider 
described a communication strategy for dealing with intermediate scores:
And I try to prepare them upfront. You know, I’ll say, before we get the results if I 
talk to them ahead of time, that an intermediate score can be difficult to sort out and 
that if it’s closer to high risk we might lean towards chemotherapy. If it’s closer to 
low risk, we might lean against it just depending upon other factors and stuff. If you 
come back in the intermediate group, we’re going to make our decisions the same 
way we used to 10 years ago as if this didn’t exist. I definitely warn them about it.
3.3 Making Decisions
Identifying and developing a plan for addressing uncertainty around decision-making was 
further developed in this domain before and after ordering ODX testing in two ways: (1) 
preparing for/deliberating about choices and (2) implementing choice and action decisions. 
During preparation and deliberation, providers presented options for decision-making and 
elicited patient preferences for ODX testing and chemotherapy. For both choices, providers 
used resources provided by Genomic Health, for example, visual displays of a patient’s 
ODX test results and risk of recurrence:
Sometimes I’ll show them that bar graph on page two [of the results report] which 
shows sort of the confidence intervals. I find that more helpful…. But I’ll say, 
“Look, your cure rate might go up 5%. It might not go up at all. It could even be 
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harmful.” I said, “It’s not like this high risk one where you can see 25%, that bar go 
up.” I’ll say, “We’re not really sure about this. And that’s an average of all of the 
ones in the intermediate. So, it’s the good intermediates and the bad intermediates.”
After discussing the test results, providers and patients made decisions about initiating 
adjuvant chemotherapy and formed a treatment action plan, including discussion of adjuvant 
chemotherapy and endocrine therapy. For example:
And generally, obviously if it’s a low risk group it’s an easy discussion. “Great 
news. You don’t need chemo. You’re not going to benefit from it.” For the high risk 
patients, again there’s that visual picture where they see the lines going up and 
usually it’s a no-brainer for most and you can explain how the addition of 
chemotherapy will likely impact their disease free survival, overall survival. We 
talk about the chemotherapy options at that point…side effects…and anti-estrogen 
therapy.
Deliberation for patients with intermediate risk scores was more complex because of 
uncertainty about the benefit of adjuvant chemotherapy [3]. As such, there is overlap 
between managing uncertainties and making decisions. Providers did not discuss other 
aspects of making decisions, including reflecting on the patients’ choice and experience and 
eliciting the patient’s preferred role in decision-making.
3.4 Cross Cutting Themes
Providers discussed aspects of patient-centered communication that crossed all domains, 
including care team members’ roles during ODX testing and adjuvant chemotherapy 
decision-making. One surgical oncologist said:
I’m the first person to see them and they’re going to go on and see radiation 
oncology after surgery. So, I usually tell them kind of broadly that the next steps of 
treatment are going to depend on the surgical pathology. And if the lymph nodes 
are involved, many women will get chemotherapy. But if the lymph nodes are 
normal, the medical oncologist will likely go on and order a test called the 
Oncotype DX test and this tests the tumor itself to determine how much 
chemotherapy would benefit these patients above and beyond endocrine therapy.”
Because decision-making and interpretation can span surgical oncology, medical oncology, 
and pathology, it may be important for patients to understand the roles of cancer care 
physician in discussing ODX testing and their diagnostic and treatment trajectory. Other 
cross-cutting considerations were ensuring enough time for these discussions and using an 
attentive listening approach. To this end, most providers held discussions related to ODX 
over multiple routine visits. This not only broke the conversation into smaller, more 
digestible pieces of information, but also allowed repetition to reinforce patient’s 
understanding of critical information.
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4. Discussion
4.1 Discussion
Providers face challenges when discussing complex genetic technologies and their treatment 
implications with their cancer patients [6]. Patient-centered communication strategies are 
critical to ensure that patients’ preferences are considered. Our findings demonstrate that 
providers already are employing aspects of patient-centered communication techniques to 
facilitate discussion about ODX testing and adjuvant chemotherapy initiation for early stage, 
hormone receptor positive breast cancer patients.
Overall, providers reported spending significant time sharing background information with 
patients about ODX testing and adjuvant chemotherapy. Prior to exchanging information, 
some providers elicited patient knowledge and experiences to gauge what patients needed to 
know. To address identified knowledge gaps, providers used various strategies ranging from 
metaphors to technical descriptions of tumor biology. Furthermore, most providers utilized 
visuals to explain ODX testing and chemotherapy and gave these resources to patients for 
reference. Notably, this exchange of information occurred before and after ordering ODX 
testing.
Providers expressed uncertainty around how well patients understood complex risk and 
genetic information. Current literature supports these concerns, demonstrating that, on 
average, patients have poor understanding and knowledge of ODX testing [7, 11, 12]. This 
suggests that there may be room for improvement in information exchange about ODX 
testing with patients. Though not discussed by providers, eliciting from patients what level 
of detail and information they want or need may be important for tailoring informational 
exchange for each individual patient. Tailoring informational content and exchange 
strategies to a patient’s knowledge, needs, beliefs, and preferences may help achieve more 
effective patient communication.
Discussing uncertainty was also an important aspect of patient-centered communication. 
Providers helped patients identify, understand and resolve uncertainty about ODX testing, 
especially for women with intermediate risk scores. Strategies for addressing anxiety and 
stress related to uncertainty were not discussed. It is possible that patients may receive such 
support through mechanisms other than the medical provider, such as support groups and 
counseling. It is also possible that providers did not feel qualified to implement strategies 
that address emotional aspects of uncertainty. Our interview guide did not explicitly probe 
about providers’ use of such strategies, which may have led to under-representation of these 
topics in our data.
Finally, providers used patient-centered approaches when discussing decision-making. They 
tried to present clear choices about ODX testing and adjuvant chemotherapy. Providers 
incorporated both clinical evidence and patient preferences into these conversations, 
sometimes giving patients the ODX test result reports to help inform decision-making. Two 
aspects of decision-making were not often discussed: (1) the role the patient wished to take 
in decision-making and (2) re-evaluating the decision. This, may in part, result from not 
having interview questions, which explicitly asked about these topics. However, 
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determination of what role the patient wants to take in deciding about the use of genetic tests 
and interpretation of the results may be an important first step in the decision-making 
process. On the back end, providers may wish to reflect and evaluate how the patient feels 
about her decisions around using ODX testing and adjuvant chemotherapy.
Our study has several limitations. First, our small sample of oncologists in North Carolina 
limits the generalizability of our findings. Furthermore, oncologists who agreed to 
participate in this study may differ from those who did not respond. The majority of 
participants had an academic affiliation and our results may not generalize to physicians 
practicing outside of academic-affiliated sites. For example, evidence suggests that providers 
with academic affiliations may be more likely to specialize in one type of cancer and may be 
more likely to adopt innovations [13], such as ODX, possibly making them more 
knowledgeable about ODX than physicians in other practice settings. Second, we did not 
assess three domains of patient-centered communication: recognizing and responding to 
emotions, fostering healing relationships, and enabling self-management and patient 
navigation. A priori, we viewed these domains as farther removed from our primary focus on 
the uptake and use of ODX testing and subsequent decision-making; as such, we did not ask 
questions for these domains during interviews. Third, the study is based on physicians’ self-
report and, as such, we do not know whether it reflects their actual behavior. While themes 
around emotional aspects of managing uncertainty, assessing decision-making preferences, 
and evaluating decisions did not emerge, it is possible that providers do address these sub-
domains within patient interactions. Notably, patient-centered communication must be 
assessed not only through eliciting information from providers, but also from patients: 
Future research should investigate patients’ preferences about ODX communication to 
determine how well patient preferences and provider communication strategies are 
aligned [14, 15].
4.2 Conclusions
We found that oncologists reported using patient-centered communication strategies to 
discuss ODX testing and decision-making about adjuvant chemotherapy. More attention to 
patient communication preferences, re-evaluating treatment decisions, and developing 
emotion-based strategies for handling anxiety and stress related to uncertainty may be 
warranted. For example, providers should engage with patients on their preferred role in 
treatment decision-making[8], and assess the need for psychosocial interventions among 
patients presenting with anxiety[16]. Engaging in patient-centered communication about 
these complex genetic technologies is critical to respecting patients’ preferences in decision-
making. Future research into the effectiveness of the patient-centered communication 
framework, as well as the nuances of describing genetic technologies is needed. This will 
become increasingly important as cancer care continues to become more targeted through 
the use of precision medicine.
4.3 Practice Implications
This study provides insights on how patient-centered communication can be integrated into 
the clinical practices of oncologists as they discuss both complex genetic testing and how to 
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use test results to help make decisions consistent with patients’ preferences. This patient-
centered approach to communicating ODX testing and treatment planning may serve as a 
model as we move into an era of precision medicine both within and outside cancer care.
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Table 1
Characteristics of participating oncologists, their patients, and practices.
Characteristics Mean
Provider
Gender (%Male) 53.3
Race (% White vs. Non-white) 86.7
Oncology Specialty (% Medical vs. Surgical) 66.7
Years of practice 15.8 ± 7.8
Number of ODX ordered per month 4.4 ± 3.4
Patient Mix
Medicaid (%) 20.7
Uninsured (%) 10.5
Non-White (%) 38.1
Breast Cancer Patients (%) 56.4
Breast Cancer Patients/wk (%) 25.1 ± 13.9
Breast Cancer patients with HR+ breast cancer (%) 68.1
Practice Academic Affiliation (%) 73.3
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